SLC5A2 and type 2 diabetes mellitus: Since results from large cardiovascular trials indicated that SGLT-2 inhibitors might increase the risk of leg amputations, this study aims to determine whether dapagliflozin therapy affects peripheral vascular oxygenation, as measured by transcutaneous tissue oximetry, in patients with type 2 diabetes and PAD compared to patients without PAD.